Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Sperm Quality

Interventions

BIOLOGICAL

Certolizumab pegol

400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously

BIOLOGICAL

Placebo

2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously

Trial Locations (1)

Liège